MD Anderson Cancer Center

A new series from Union for International Cancer Control (UICC) and produced for them by?BBC StoryWorks celebrates the determined pursuit of new and exciting treatments and developments in cancer detection, screening and treatment. Our Dr. Kathleen Schmeler is featured for #RewritingCancer and follows her work for women in Zambia. Watch more: https://bbc.in/3XC0Fe2 #EndCancer

“The RECORD trial offers valuable data and insights that support the use of therapy in the palliative care setting in order to provide patients with greater comfort,” says our Dr. David Hui. Read about findings presented at ESMO 2024. #CancerResearch #EndCancer

“This first-in-human trial with AZD8205 demonstrated promising clinical activity, especially in gynecologic tumors and breast cancer, and a safety profile consistent with the mechanism of action,” says our Dr. Funda Meric-Bernstam of research shared at ESMO 2024. “We look forward to additional data from this study as we continue working to advance ADCs as an emerging class of cancer therapy.” #CancerResearch #EndCancer

Mimi and Dick Murphy have been volunteering at MD Anderson since 2011. Learn why it is so important to them to give back. #EndCancer

We are collaborating with Rice University to the launch the Center for Operations Research in Cancer. With Rice’s expertise and MD Anderson’s Institute for Data Science in Oncology, the new center will harness mathematical modeling and data science to optimize treatment delivery, improve therapy outcomes and streamline operations at the nation’s leading cancer center and beyond. Learn more. #EndCancer

MD Anderson experts are presenting out-of-the-box immunotherapy research at ESMO 2024, including new strategies for preventing lung cancer and treating rare cancers. #CancerResearch #EndCancer

Later this week, MD Anderson experts will present clinical advances across a variety of cancer types at ESMO 2024. Read about some of the research they'll be sharing here. #CancerResearch #EndCancer

In the first-in-human Phase Ia Beamion LUNG-1 trial, research led by our Dr. John Heymach showed that zongertinib had promising overall response and disease control rates for patients with HER2 positive solid tumors and HER2 positive NSCLC. Learn more about this study and more MD Anderson research presented at the 2024 World Conference on Lung Cancer. #CancerResearch #EndCancer

The best part of managing diabetes in a place like MD Anderson is that it allows me to give patients back some measure of control over their lives, says our Dr. Sonali Thosani. Read her story. #EndCancer

“In both of those areas, you always want to innovate and create something that did not exist before," says our Dr. Hagop Kantarjian of the similarities between art and medicine. Read his story. Leukemia Department - Hagop Kantarjian, M.D. #EndCancer